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Abstract
Purpose Severe combined immunodeficiency (SCID) is
characterized by failure of T lymphocyte development and
absent or very low T cell receptor excision circles (TRECs),
DNA byproducts of T cell maturation. Newborn screening
for TRECs to identify SCID is now performed in several
states using PCR of DNA from universally collected dried
blood spots (DBS). In addition to infants with typical SCID,
TREC screening identifies infants with T lymphocytopenia
who appear healthy and in whom a SCID diagnosis cannot
be confirmed. Deep sequencing was employed to find
causes of T lymphocytopenia in such infants.
Methods Whole exome sequencing and analysis were per-
formed in infants and their parents. Upon finding deleterious
mutations in the ataxia telangiectasia mutated (ATM) gene,
we confirmed the diagnosis of ataxia telangiectasia (AT) in
two infants and then tested archival newborn DBS of addi-
tional AT patients for TREC copy number.
Results Exome sequencing and analysis led to 2 unsuspect-
ed gene diagnoses of AT. Of 13 older AT patients for whom
newborn DBS had been stored, 7 samples tested positive for
SCID under the criteria of California’s newborn screening
program. AT children with low neonatal TRECs had low
CD4 T cell counts subsequently detected (R00.64).
Conclusions T lymphocytopenia in newborns can be a feature
of AT, as revealed by TREC screening and exome sequencing.
Although there is no current cure for the progressive neurolog-
ical impairment of AT, early detection permits avoidance of
infectious complications, while providing information for fam-
ilies regarding reproductive recurrence risks and increased
cancer risks in patients and carriers.
Keywords Ataxia telangiectasia . SCID . newborn
screening . TREC . whole exome sequencing
Introduction
Severe combined immunodeficiency (SCID), characterized
by extremely low or absent T cell production, defective T
cell function and absent antibody responses, can be caused
by defects in any of several genes and if untreated leads to
early death due to infections [1, 2]. Population based new-
born screening for SCID has been recommended to identify
affected infants before the onset of devastating infections so
that effective treatment can be provided [3–6]. A newborn
screening test for SCID, now implemented in several states,
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ascertains T-cell receptor excision circles (TRECs), DNA
byproducts of T cell antigen receptor gene rearrangement, as
a biomarker of normal T cell development [5, 7–10]. TRECs
are measured by quantitative PCR (qPCR) of DNA isolated
from infant dried blood spot (DBS) samples universally
collected in nurseries. For infants with undetectable or low
TRECs, or with unsatisfactory DNA amplification, a differ-
ential white blood count and analysis of lymphocyte subsets
by flow cytometry are obtained to establish the absolute
number of naïve T cells, after which further clinical and
laboratory evaluations are performed to arrive at a definitive
diagnosis [9].
Beyond typical SCID cases, TREC screening has detected a
spectrum of infants with inadequate numbers of diverse, au-
tologous T cells. As predicted before the start of screening,
“leaky” SCID and Omenn syndrome, both due to hypomor-
phic mutations in SCID genes, have been found in infants with
low TRECs, as have cases of DiGeorge syndrome/chromo-
some 22q11 deletion in which a substantial degree of thymic
insufficiency exists. In addition, secondary causes of T lym-
phocytopenia have included abnormal loss of T cells from the
peripheral circulation, such as with chylothorax or hydrops. A
challenging and less anticipated category of cases with abnor-
mal TREC results has been the infants with persistent T
lymphocytopenia of 300–1,500 T cells/μL, no maternal T cell
engraftment, and absence of identified deleterious mutations in
common SCID genes. These infants have been designated as
combined immunodeficiency (CID) or SCID variants by
TREC newborn screening programs [9]. CID or SCID variant
cases have been of particular interest, providing an opportunity
to discover previously unappreciated causes of newborn T
lymphocytopenia. In the absence of clues to narrow the num-
ber of potential candidate genes to account for variant SCID in
asymptomatic infants who appear healthy, high throughput
deep sequencing may be useful; this approach has led to gene
identification in other primary immunodeficiencies [11–13].
Using whole exome sequencing (WES), we found two
infants with variant SCID who had deleterious mutations in
the Ataxia Telangiectasia Mutated (ATM) gene. Prompted
by the prospective discovery of these patients’ diagnoses
and a recent report of low TRECs in archived DBS from
cases of ataxia telangiectasia (AT) [14], we reviewed 13
cases of AT in our clinical cohorts. By retrieving their
residual DBS samples taken in the newborn nursery and
measuring their TREC numbers, we showed that over half
of AT patients could be identified as abnormal, making AT a
secondary target of SCID screening.
Methods
Subjects Infants V003 and V004 were identified as positive
by routine California SCID screening by TREC test and
confirmed to have T lymphocytopenia. Informed consent
for research, including cellular immune studies and WES,
was obtained for the infants and their parents under
approved protocols at Children’s Hospital Los Angeles
(CHLA) and the University of California San Francisco
(UCSF). Additional patients from the pediatric immunology
services at CHLA and UCSF were enrolled with institution-
al review board approval.
DNA Samples Genomic DNA from EDTA anticoagulated
whole blood was prepared using a Gentra Puregene Blood
kit (Qiagen USA: Germantown, MD).
Exome Sequencing Libraries were prepared by ligating a
pair of TruSeq adaptors (Illumina: San Diego, CA) to ge-
nomic DNA sheared to a mean fragment size of 200–300 bp
(S2 sonicator, Covaris: Woburn, MA). Specific sequence
tags were added to different samples to differentiate each
individual of origin. Libraries with these adaptors and bar-
code sequences were enriched with 10 cycles of PCR. For
infant V003 and parents, exon capture was performed by
pooling 500 ng of each of 6 libraries incubated with Illu-
mina TruSeq version 2 biotinylated exon-encoded DNA
oligonucleotides for 20 h. For V004 and parents, exon
capture was performed by incubation with a Roche Nimble-
gen version 3 capture array. Exon-enriched DNA was cap-
tured with streptavidin-labeled magnetic beads, washed and
eluted. Capture reactions were repeated to enhance specific-
ity. After 10 cycles of DNA amplification, the exome librar-
ies were sequenced (HiSeq2000, llumina). Paired 100 bp
end reads were generated (>50 M reads/subject), to yield an
average of >65 reads covering the targeted regions with
>90 % covered by at least 10 reads.
Whole Exome Sequence Analysis Raw reads were aligned
against reference genome hg19 using BWA (0.5.9) software
[15]. The resulting files were converted to compressed bi-
nary format (BAM), sorted by coordinate, indexed, and
marked for PCR duplicate reads using the Picard toolkit
(http://picard.sourceforge.net). BAM files were processed
to reduce artifacts and improve call accuracy using GATK
software (v 1.4.15) [16, 17]. Specifically, local realignment
was performed around known insertion or deletion (indel)
locations, and base quality scores were re-calibrated us-
ing co-variates such as position in read and sequencing
chemistry effect.
Variants were called using the GATK UnifiedGenotyper.
The called single nucleotide polymorphisms (SNPs) had
their scores re-calibrated by variant quality score recalibra-
tion (VQSR) using the exomes in this report plus 24 others
sequenced at our site. HapMap v3.3 and the Omni chip array
sets from the 1,000 genomes project (October, 2011 release)
were training data, and HapMap 3.3 provided truth sites [18,
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19]. A truth sensitivity cutoff of 99 % was used. For indel
recalibration and quality selection, we used QD <2.0, Read-
PosRankSum <−20.0, Fischer Strand >200.0. Additional
annotations including region, effect, dbSNP 135 and 1,000
genomes membership and OMIM phenotype were added
using custom scripts. Filtering of exome data was performed
using a combination of custom scripts and vcftools [20].
Aligned sequences were viewed using the Savant Genome
Browser [21].
PCR and Genomic Sequencing ATM exons 7, 10, 39, and
46 were amplified from genomic DNA using published
primers (labeled as exons 9, 12, 41, and 48 in Thorstenson
et al. [22]) with an M13 extension 5′ to each reverse primer
as follows:
ATMe7_Forward 5′ - GTA AAA CGA CGG CCA
GTC AGC ATA CCA CTT CAT AAC TG
ATMe7_Reverse 5′ - TCA TAT CCT CCT AAA GAA
CAC
ATMe10_Forward 5′ -TGT GAT GGA ATA GTT TTC
AA
ATMe10_Reverse 5′- GTA AAA CGA CGG CCA GTT
GTG ATG GAA TAG TTT TCA A
ATMe39_Forward 5′- TGT GGT TTT TGG GAATTT
GTA
ATMe39_Reverse 5′- GTA AAA CGACGG CCA GTT
GTG GTT TTT GGG AAT TTG TA
ATMe46_Forward 5′ - GTA AAA CGA CGG CCA
GTT CTT GTC ACT ACA AAA GTT CCT TT
ATMe46_Reverse 5′ - TCT TTT TCC CTC AGG CTT
TC.
Sequencing was performed with the M13 forward primer,
and results were compared with reference ATMNG_009830.1,
using Sequencher 4.10.1 software (Gene Codes Cooperation:
Ann Arbor, MI).
Neonatal Dried Blood Samples Residual DBS originally
collected for routine NBS and stored at −20° by the Genetic
Disease Laboratory (GDL) of the California Department of
Public Health (CDPH) were retrieved, and TREC and β-
actin gene copy number determined by the GDL newborn
screening laboratory, using the protocol of Chan and Puck
[5] modified for high throughput and implemented by Per-
kinElmer, Inc (lab within a lab at California Department of
Public Health, Richmond, CA; parent company based in
Hershey, PA) with cutoff values as reported [9].
Results
Infant Clinical and Immunologic Findings Newborns in
California are screened for SCID and classified as positive
if TREC copy number is ≤5 with β-actin >5,000 copies, or
TREC copy number is between 6 and 25 with β-actin
>10,000 copies. The tests are classified as incomplete and
are repeated if there are low TRECs, but also low copies of
the β-actin gene segment amplified as a control. T cells are
measured by flow cytometry in cases that are positive or that
have two incomplete DBS samples.
Infants V003 and V004 were unrelated, healthy females
born at term following normal pregnancies. Family history
for both was negative for immune disease or consanguinity.
Lymphocyte flow cytometry was ordered for infant V003
after two DBS yielding incomplete results, while V004 had
an initial positive result with 21 TRECs and 13,300 β-actin
copies (Table I).
At age 3 months Patient V003 had a normal total white
blood cell count, but only 4 TRECs/μL (with normal β-
actin copies) and only 1,600 lymphocytes/μL (Table I).
There were 996 T and 52 B cells/μL (normal >2,000 and
>300, respectively), and the number of CD45RA naïve CD4
T cells was low. NK cell number was normal. Low T and B
cell numbers persisted, and low IgG levels with failure to
produce antibodies after vaccination led to institution of
immunoglobulin replacement and tr imethoprim-
sulfamethoxazole antibiotic prophylaxis. Lymphocyte pro-
liferation to phytohemagglutinin and TCR Vβ diversity
assessed by spectratyping [23] were normal, but an Epstein
Barr virus transduced B cell line from the patient had only
half normal phosphorylation of STAT5 in response to IL-2
[24], suggesting an intrinsic lymphocyte impairment. Later,
at age 14–16 months, V003 was reported by her mother to
have “unsteady” gait; physical examination first showed
mild truncal ataxia at 20 months.
Infant V004 had flow cytometry at 21 days of age,
showing only 1,060 T cells, with low CD45RA naïve helper
CD4 T cells (Table I). B and NK cell numbers and lympho-
cyte proliferation were normal, but Vβ spectratyping
showed decreased T cell diversity (not shown). As with
infant V003, in vitro phosphorylation of STAT5 after IL-2
activation was diminished, but not absent, as would be the
case in SCID due to defects in the IL-2 receptor common γ
chain or Janus kinase 3 [9, 24]. Physical examination of
infant V004 has been normal to date, but she did not mount
robust antibody to T-cell dependent protein-conjugated H.
influenzae vaccination.
Exome Analysis and Gene Confirmation To investigate the
genetic etiology underlying their observed immunodeficient
status, DNA samples from V003, V004 and their parents
were subjected to WES to generate a list of small nucleotide
polymorphism (SNP) and small insertion or deletion (indel)
variants. These lists were filtered to retain successively
fewer candidate variants as shown for SNPs and indels
separately for each infant in Fig. 1b. After initial quality
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filtering and removal of variants common enough to be found
in dbSNP 135 and the 1,000 Genomes database, further filters
were applied to keep only the non-synonymous variants lying
in captured exonic and splice-site regions of genes, and only
those variants with a high (>30) genotype quality score
(Fig. 1a, step 4).
We then further limited the disease gene candidates either
by function of gene products (Fig. 1a, yellow) or by genetic
segregation (red). For functional selection, we used a list of
49 candidate genes involved in T cell development or
reported to be defective in human primary T cell deficien-
cies by the International Union of Immunological Sciences
Committee on Primary Immunodeficiency [25]. In infant
V003, this filtering left three heterozygous variants, of
which two were frameshift deletions within the ATM gene.
Aligned sequence reads supporting one of these, variant
c1787delAA (K468fs), a two base deletion in ATM exon
10, are illustrated in Fig. 2a. Evidence for the second ATM
variant of V003, c6238delA (F1952fs), a single base dele-
tion in exon 39, was equally robust (not shown).
In infant V004, inclusion in the T cell gene list yielded
only two heterozygous SNPs, both in ATM, c.1260C>T
(P292L), and c.7064C>T (R2227C). These results sug-
gested disease-causing compound heterozygosity in both
V003 and V004.
By the segregation filtering method, we retained gene
altering variants fitting a homozygous or compound hetero-
zygous model of recessive inheritance - that is, those genes
for which the patient inherited one rare allele from each
parent - using exome data from each infant/parent trio. By
this method, 5 candidate genes remained in the family of
V003 and 9 in the family of V004. By filtering out variants
also found in the unrelated local exomes used for VQSR,
these numbers were reduced to 3 and 7 genes, respectively.
Infant V003 shared the ATM mutation K468fs with her
mother and F1952fs with her father, while V004 shared
Table I Immunologic Phenotype of Infants Identified by SCID Newborn Screening
Infant V003 V004
Age 3 ma 5.5 m 21 daysb 7 m
TREC (normal >25) 4c 21
Beta-actin (>10,000) 10,000 13,300
WBC (5,000–19,500 cells/μL) 7,100 3,530 4,500 5,320
ALC (2,500–16,500) 1,600 2,189 2,000 3,032
CD3 T cells (2,550–5,500) 996 615 1,060 1,397
CD4 T-helper cells (1,600–4,000) 749 502 600 777
CD8 T-cytotoxic cells (560–1,700) 185 172 340 400
CD3/CD4/CD45RA (1,200–3,700) 456 360
CD3/CD4/CD45RO (60–900) 299 180
CD19 B cells (300–2,000) 52 84 440 1,232
CD16/56 NK cell (170–1,100) 347 1,605 300 381
IgG (165–781 mg/dL) 156 414
IgA (25–154) < 7 17
IgM (31–103) 37 66
IgE (<17 IU/mL) < 2
Anti-tetanus (>0.1 IU/mL)d 0.07 3.73
Anti-H. influenzae type b (>1 mcg/ml)d < 0.15 0.68
Proliferation to PHA normal normal
Diversity of TCR Vβ repertoiree normal decreased
IL-2 induced STAT5 phosphorylationf 55% of control 75% of control
a Initial and follow-up dried blood spot samples from infant V003 were incomplete, with low TRECs, but also low β-actin; despite multiple
notifications from the newborn screening program, there were delays between the initial screening result and a follow-up blood sample being
submitted for both flow cytometry and a third TREC screen, which was positive
b Initial screening result from infant V004 was positive at age 16 days; follow-up flow cytometry was performed at age 21 days; this timeline is
typical for the CA SCID screening program
c Abnormal values displayed in bold type
d Serum antibody concentrations following 3 immunizations
e Spectratyping according to Sarzotti et al. [23]
f EBV transformed cells exposed to IL-2, normal control0100 % [24]
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P292L with her mother and R2227C with her father. The
other genes harboring parentally shared variants were not
associated with any recognized immunologic phenotype.
Sanger sequencing confirmed the ATM mutations seen
by exome sequencing for both V003 (Fig. 2b) and V004, as
well as in both sets of parents (results not shown).
Subsequent to the sequence findings, both infants under-
went measurement of serum alpha fetoprotein (AFP) levels;
elevated AFP compared to age-adjusted normal ranges is a
reliable marker for AT in children. V003 at age 16 months
had AFP 307 μg/L, while V004 at 7 months had 112 μg/L
(normal range for these ages, 8–80 μg/L [26]). Western blot
showed absent ATM protein in both patients (data not
shown).
TREC Analysis in Additional AT Cases To test whether T
lymphocytopenia detected by low TRECs is common in
infants with ATM mutations, medical records of California-
born patients with AT followed at CHLA and UCSF over
the past 25 years were reviewed, and their residual neonatal
DBS were retrieved by the CDPH for TREC testing. As
summarized in Table II, 13 patients with AT, 9 females and 4
males, none of whom had been suspected to have AT at
birth, had their newborn DBS samples retrieved. Upon
testing, 7 samples had TRECs ≤25; thus newborn screening
would have flagged these AT patients in infancy to receive
follow-up lymphocyte immunophenotyping. The AT patients’
ethnic distribution was not different from the overall distribu-
tion of California births.
All 13 AT patients initially presented with symptoms of
ataxia and abnormal gait between ages 12 months and
8 years (median 17 months). Patients experienced a delay
from 2 months to 10 years between onset of symptoms and
AT diagnosis, which occurred between ages 1.5 and 12
years (median age 3 years 5 months). At diagnosis all 13
AT patients had high serum AFP concentrations, from
16.8 μg/L at 1 year 7 months (Patient 6) to 310 μg/L at
12 years 3 months (Patient 3). AFP levels in utero and at
birth are high, but fall to <8 μg/L for children over age 2
[26]. We confirmed the correlation between AFP and age
(R00·63), as reported [26, 27]. Furthermore, all 13 patients
had T lymphocytopenia with <1,500 T cells/μL at the time
of their diagnosis of AT; subsequently, 8 had recurrent
immunological manifestations including soft tissue infec-
tions (1 patient), cutaneous and visceral granulomas (3
patients), and chronic respiratory infections (4 patients).
Out of 13 patients, 4 also had hematological malignancies,
leading to fatality in Patients 1 and 10.
Comparing the 7 patients whose SCID newborn screens
were positive (≤25 TRECs with normal β-actin) vs. the 6
whose were negative (TREC >25 copies), there were no
significant differences in age at presentation with neurolog-
ical symptoms, AFP levels, total CD3 T cell counts, or time
between symptom onset and diagnosis, though our T cell
information from retrospective chart review did not provide
lymphocyte subset data in infancy; the median age for the
first recorded immune panel was 4 years. Interestingly, there
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Fig. 1 WES variants filtering paths. a Trapezoids represent filters with
resulting numbers of variants retained after each step indicated by a
circled digit. Starting with initial total variant lists (1), filters were
applied for quality (2) and then to keep rare alleles (3) that alter splice
sites or produce non-synonymous codon changes and are absent in
local exomes (4). Subsequent strategies were: focusing on variants
from a list of genes associated with T cell phenotypes (yellow shading,
5); or demanding a recessive inheritance pattern (red shading, 6). b
Numbers of variants retained for the exome of each proband, V003 and
V004, after each filtering step in A, showing individual numbers of
SNPs/indels, left, and genes harboring variants, right. For steps (7) and
(8), number of genes containing candidate variants in each proband are
shown. The final lists of genes at step (8) are as follows: for V003 –
ATM, PCDH15, PHF2; for V004 – ATM, EYS, PCDP1, PRUNE2,
SH3D21, TSHZ3, TTN. *, 2 variants, both in the ATM gene. **, genes
with rare variants conforming to a recessive disease model in the
family trio
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patients’ archived newborn DBS and their subsequently
measured CD4 T cell counts (R00·64). Further analysis with
a larger sample of AT patients might reveal additional rela-
tionships between newborn TREC numbers and phenotypic
clinical and laboratory features of AT.
Discussion
Newborn screening by TRECs was developed with SCID as
its primary target, but a spectrum of conditions are also
identified that feature clinically significant T lymphocyto-
penia, defined by the California newborn screening program
as <1,500 T cells/μL or a lack of CD45RA naïve T cells.
Through screening with the TREC assay, two apparently
healthy California newborns with unexplained lymphocyto-
penia were identified to have AT, with deleterious mutations
in the ATM gene detected by WES and confirmed by Sanger
sequencing, AFP elevation and undetectable ATM protein
expression. The abnormal TREC screening results in infants
V003 and V004 allowed physicians to avoid exposure to
live attenuated rotavirus vaccine, contraindicated in infants
with T cell immunodeficiency. Although T and B cell im-
munodeficiency is a well recognized, but variable feature of
AT patients of older ages, the degree of immune compro-
mise in early infancy has not been documented. Our early
diagnosis of AT has provided an opportunity to observe
prospectively the evolution of immunological, neurological
and malignant features of AT.
Clinical features of AT include the loss of motor mile-
stones between 1 and 2 years of age, with falls, slurred
speech, oculomotor apraxia, and truncal instability. Ocular
telangiectasias appear between 2 and 8 years. Family histo-
ry, if positive, may assist diagnosis. Laboratory features
often include absent IgA and always include elevated
serum AFP, though the interpretation of AFP requires age-
adjustment because this fetal serum protein remains abun-
dant in infancy [26, 27]. Magnetic resonance imaging of the
brain is unhelpful in early disease, as cerebellar abnormali-
ties become apparent only after 2 years [28]. Increased
cellular radiosensitivity is found in AT, though assays may
not differentiate AT from other defects with defective DNA
repair [29]. Thus, low TRECs and T lymphocytopenia
detected by newborn screening can be the earliest and sim-
plest warning that AT may be present, and validates the
hypothesis of Borte et al., who suggested that AT might be
detectable by prospective TREC screening, based on their
survey measuring TREC and kappa chain B cell excision
circles in archival DBS from patients with known primary
immunodeficiencies [14]. The large size of the ATM gene,
with 63 exons encoding an mRNA of 13,147 nucleotides,
makes genomic sequencing costly and laborious; thus, WES
may become a cost effective first line approach to examine
this gene.
Deep Sequencing in the Context of Newborn Screening
with TRECs
Our study demonstrates the value of a “short-list” of gene
candidates of interest when searching deep sequencing data
for rare, disease-causing variants. By focusing on a list of
genes known to be associated with T-cell deficiencies, we
were able to single out clinically relevant mutations with a
minimum of other filters. The variants in our families oc-
curred in regions with excellent coverage, as illustrated by
the abundant bidirectional reads in Fig. 2a. However, high-
quality coverage of all AT exons by WES or other deep
sequencing is not guaranteed. In the exome datasets of our
infants and their parents, between one and four ATM exons
had <15x coverage, arguably inadequate to make accurate
Fig. 2 Sequence evidence for a heterozygous exon 10 2-bp deletion of
ATM in infant V003. a Aligned paired-end reads from whole exome
sequence, chr11:108121571–108121612, viewed with Savant Genome
Browser.18 Center black bars indicate deletion of c1787delAA,
K468fs, found in 27 of the 54 reads that include this sequence. Dark
blue, forward reads; light blue, reverse reads. Colored rectangles,
mismatch base calls compared to reference genome (judged to be
artifacts because of singular occurrence). b Sanger genomic reverse
sequence confirming the heterozygous deletion. c Reference and mu-
tated amino acid codons, showing the frameshift, which led to 17
missense codons followed by a termination
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variant calls. As quality, coverage and affordability of
deep sequencing improve, the chance of missing a var-
iant will decline, but should be considered when using
WES clinically.
Another consideration regarding deep sequencing analy-
sis is the utility of filtering against local exome data other
than dbSNP and 1,000 Genomes. Many indels are not
annotated in existing databases despite being relatively com-
mon. Thus we observed large numbers of indels compared
to SNPs persisting through the first 3 steps of our analysis
(Fig. 1b). Most indels were removed by genotype quality
filtering against local exomes. Also, indel calling is less
reliable than SNP calling; filtering indel variants against
unrelated local exomes reduces the rate of local errors and
artifacts.
Infant V003’s gene mutations have not been previously
reported, but, like most ATM mutations, produce early stop
codons, predicted to lead to nonsense mediated decay of
mRNA [30]. One of infant V004’s mutations has been
reported [31]; the other is predicted to be damaging by
SNAP and Polyphen-2 algorithms [32, 33].
Epidemiology and Public Health Considerations.
We have demonstrated the ability to diagnose AT within the
context of a newborn screening program and have provided
documentation for the first time of sufficiently low T cell
counts in two infants with AT in the first months of life that
live vaccines should be avoided. The incidence of AT has
been reported to be between 1:40,000 and 1:100,000 births
[34] with high rates in some populations due to founder
mutations [35]. A more recent estimate was lower,
1:300,000 births [36]. The two infants reported here are
the only newborns found to have AT in the first 18 months
of California’s SCID newborn screening program, in which
over 740,000 infants were screened. With 7 of 13 AT cases
(54 %) from archived samples having abnormal TREC
screening, our data in the highly diverse California popula-
tion suggest an incidence figure around 1:200,000. Califor-
nia has the largest number of annual births of any state in the
U.S., and population-based newborn screening with TRECs
will provide a prospective, unbiased method to establish the
incidence of AT.
The detection of AT by newborn screening illuminates
challenges surrounding the inclusion of new tests into a
public health screening program. Currently there is no cure
for AT; the neurological deterioration is progressive and
irreversible such that patients usually become wheelchair
dependent by their teenage years, and lifespan is decreased.
In addition, patients with AT have increased risk for malig-
nancies, attributed to compromise of DNA repair mecha-
nisms. Consistent with the reported 30–40 % lifetime risk
and 10–15 % childhood or early adulthood risk of lymphoid
malignancy, 3 of our 13 retrospective patients had lympho-
mas and one had leukemia [37, 38]. ATM heterozygous
mutation carriers also have an increased risk of breast cancer
as well as other epithelial malignancies [39, 40]. Thus,
although screening programs are designed to identify
newborns with diseases for which there are treatments, the
early diagnosis of AT as a secondary target of TREC screen-
ing for SCID can provide important information for family
and genetic counseling. Patients should avoid undue irradi-
ation and should be monitored for malignancy as well as
protected from infection, while carriers of ATM mutations
should be made aware of their own increased risk of cancer,
and any anti-cancer therapy they require should be tailored
in light of their increased sensitivity to radiation [41]. A
diagnosis of AT by newborn screening can also help parents
plan for the care of the affected child and obtain genetic
counseling when considering future pregnancies.
Furthermore, while there is currently no effective treat-
ment for AT, multiple lines of research are aiming towards
that goal. Antioxidant therapies [42–44], and more recently
HDAC4 inhibition [45], have shown promise in mouse
models; and in vitro experiments with human cells suggest
that for some patients ATM function could be restored using
mutation-targeted therapy [46]. For any of the potential
therapies under development, early intervention made pos-
sible by identification through newborn screening would be
most likely to show benefit by allowing therapy to take
effect before extensive degeneration of relevant tissues has
occurred.
Conclusion
This study demonstrates that T lymphocytopenia revealed
by newborns TREC screening can be an identifying feature
of AT. We also show the utility of exome sequencing to
arrive at a gene diagnosis for infants with variant SCID or
CID. Although there is no current cure for the progressive
neurological impairment of AT, early detection provides
information to improve patient management and offer fam-
ily genetic counseling. Whole exome sequencing coupled
with newborn screening in an ethnically diverse, large pop-
ulation will reveal unbiased data about rare diseases associ-
ated with T lymphocytopenia.
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